Cargando...

Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?

Recent phase II and III studies with intravenous immunoglobulin (IVIG) in patients with Alzheimer’s disease (AD) did not find evidence for the slowing of AD progression compared to placebo-treated patients, in contrast to encouraging results in pilot studies. An additional phase III trial is ongoing...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Neuroinflammation
Autor Principal: Loeffler, David A
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2014
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4265363/
https://ncbi.nlm.nih.gov/pubmed/25476011
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12974-014-0198-z
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!